Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs

被引：7

作者：

Busset, M. Droz Dit ^{[1
]}

Shaib, W. L. ^{[2
]}

Harris, W. P. ^{[3
]}

Damjanov, N. ^{[4
]}

Borad, M. ^{[5
]}

Vogel, A. ^{[6
]}

Bridgewater, J. A. ^{[7
]}

Sellmann, L.

Dadduzio, V. ^{[8
]}

Borner, M.

Snider, J. ^{[9
]}

Cantero, F. ^{[10
]}

Saulay, M. ^{[11
]}

Braun, S. ^{[11
]}

Mazzaferro, V. ^{[1
]}

Javle, M. ^{[12
]}

机构：

[1] Fdn IRCCS, Ist Nazl Tumori Milano, Hepatopancreatobiliary & Digest Surg, Milan, Italy

[2] Emory Univ, Atlanta, GA 30322 USA

[3] Seattle Canc Care Alliance, Seattle, WA USA

[4] Temple Univ, Ctr Canc, Philadelphia, PA 19122 USA

[5] Mayo Clin, Ctr Canc, Scottsdale, AZ USA

[6] Hannover Med Sch, Gastro Hepato & Endocrinol Dept, Hannover, Germany

[7] UCL, Canc Inst, Paul OGorman Bldg, London, England

[8] IRCCS, Ist Oncol Veneto, Padua, Italy

[9] Mercy Canc & Hematol, Springfield, IL USA

[10] Basilea Pharmaceut Ltd, Oncol Dept, Basel, Switzerland

[11] Basilea Pharmaceut AG, Dev, Basel, Switzerland

[12] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.2204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

45P

引用

页码：S1231 / S1231

页数：1